<abstract xmlns="http://www.w3.org/1999/xhtml">

<bold>BACKGROUND.</bold> Patients with rhinosinusitis account for about 30% of the total amount of otolaryngologic patients and their number is constantly growing. Currently, there is no ideal treatment for acute and especially chronic rhinosinusitis and various therapeutic approaches are still under debate.
<bold>OBJECTIVES.</bold> To evaluate the effectiveness and the safety of Cinnabsin® in acute and exacerbated chronic rhinosinusitis treatment.
<bold>MATERIAL AND METHODS.</bold> We included in our non-interventional, multicenter, prospective study 200 patients with acute and exacerbated chronic rhinosinusitis in order to evaluate the effectiveness and the safety of treatment with Cinnabsin® (while 20 out of 200 patients received additional therapy, only patients who did not receive additional therapy were taken into account in the statistical analysis; 180 patients have been treated with Cinnabsin® only and this is the basis of the statistical assessments performed). Changes in the total score of the typical symptoms of rhinosinusitis were assessed, and changes in edema, hyperemia and secretion were assessed by rhinoscopy.
<bold>RESULTS.</bold> The total score of the typical symptoms of rhinosinusitis showed a statistically significant difference between the first and final visits – v4 vs. v1 according to Pearson Chi-square (p = 0.0000) as well as in accordance with Risk Difference (RD), Relative Risk (RR), Odds Ratio (OR) ratios at the beginning and end of the treatment. The healthy status of the patients (major improvement, improvement, no complaints) was rated as 93.9% at the final visit. The efficacy of treatment (major improvement, improvement, no complaints) was rated as 93.9% at the final visit. Treatment tolerance was rated as very good in almost all patients (99.4%).
<bold>CONCLUSION.</bold> Cinnabsin® could be considered efficient in reducing the symptoms of acute rhinosinusitis, shows a very good safety profile, and could be recommended for outpatient treatment of patients with acute or exacerbated chronic rhinosinusitis, no matter the additional therapy.
</abstract>

BACKGROUND. Patients with rhinosinusitis account for about 30% of the total amount of otolaryngologic patients and their number is constantly growing. Currently, there is no ideal treatment for acute and especially chronic rhinosinusitis and various therapeutic approaches are still under debate.
OBJECTIVES. To evaluate the effectiveness and the safety of Cinnabsin® in acute and exacerbated chronic rhinosinusitis treatment.
MATERIAL AND METHODS. We included in our non-interventional, multicenter, prospective study 200 patients with acute and exacerbated chronic rhinosinusitis in order to evaluate the effectiveness and the safety of treatment with Cinnabsin® (while 20 out of 200 patients received additional therapy, only patients who did not receive additional therapy were taken into account in the statistical analysis; 180 patients have been treated with Cinnabsin® only and this is the basis of the statistical assessments performed). Changes in the total score of the typical symptoms of rhinosinusitis were assessed, and changes in edema, hyperemia and secretion were assessed by rhinoscopy.
RESULTS. The total score of the typical symptoms of rhinosinusitis showed a statistically significant difference between the first and final visits – v4 vs. v1 according to Pearson Chi-square (p = 0.0000) as well as in accordance with Risk Difference (RD), Relative Risk (RR), Odds Ratio (OR) ratios at the beginning and end of the treatment. The healthy status of the patients (major improvement, improvement, no complaints) was rated as 93.9% at the final visit. The efficacy of treatment (major improvement, improvement, no complaints) was rated as 93.9% at the final visit. Treatment tolerance was rated as very good in almost all patients (99.4%).
CONCLUSION. Cinnabsin® could be considered efficient in reducing the symptoms of acute rhinosinusitis, shows a very good safety profile, and could be recommended for outpatient treatment of patients with acute or exacerbated chronic rhinosinusitis, no matter the additional therapy.

Treatment with Cinnabsin in patients with acute and exacerbated chronic rhinosinusitis

Romanian Journal of Rhinology

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

BACKGROUND. Patients with rhinosinusitis account for about 30% of the total amount of otolaryngologic patients and their number is constantly growing....

Treatment with Cinnabsin in patients with acute and exacerbated chronic rhinosinusitis

Publié en ligne: 14 oct. 2023

Pages: 165 - 181

Reçu: 24 avr. 2023

Accepté: 23 août 2023

DOI: https://doi.org/10.2478/rjr-2023-0025

Mots clés
acute rhinosinusitis (ARS), chronic rhinosinusitis (CRS), treatment of acute rhinosinusitis, treatment of exacerbated chronic rhinosinusitis, Non-individualised Homeopathic Treatment (NIHT), Cinnabsin®

© 2023 Rumen Benchev et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Treatment with Cinnabsin in patients with acute and exacerbated chronic rhinosinusitis

Publié en ligne: 14 oct. 2023

Pages: 165 - 181

Reçu: 24 avr. 2023

Accepté: 23 août 2023

DOI: https://doi.org/10.2478/rjr-2023-0025

Mots clésacute rhinosinusitis (ARS), chronic rhinosinusitis (CRS), treatment of acute rhinosinusitis, treatment of exacerbated chronic rhinosinusitis, Non-individualised Homeopathic Treatment (NIHT), Cinnabsin®

© 2023 Rumen Benchev et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Mots clés
acute rhinosinusitis (ARS), chronic rhinosinusitis (CRS), treatment of acute rhinosinusitis, treatment of exacerbated chronic rhinosinusitis, Non-individualised Homeopathic Treatment (NIHT), Cinnabsin®